Menu Search
Equities

Gain Therapeutics Inc

GANX:NMQ

Gain Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.50
  • Today's Change0.006 / 0.41%
  • Shares traded133.78k
  • 1 Year change-55.85%
  • Beta0.3614
Data delayed at least 15 minutes, as of Sep 20 2024 17:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Gain Therapeutics Inc's revenues fell -60.62% from 140.11k to 55.18k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 17.59m to a larger loss of 22.27m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-115.33%
Return on equity-188.83%
Return on investment-170.44%
More ▼

Cash flow in USDView more

In 2023, Gain Therapeutics Inc increased its cash reserves by 61.10%, or 4.49m. Cash Flow from Financing totalled 12.64m or 22,909.28% of revenues. In addition the company used 18.87m for operations while cash from investing totalled 10.22m.
Cash flow per share-1.33
Price/Cash flow per share--
Book value per share0.4682
Tangible book value per share0.4619
More ▼

Balance sheet in USDView more

Gain Therapeutics Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 11.79m.
Current ratio2.84
Quick ratio--
Total debt/total equity0.0413
Total debt/total capital0.0396
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.